Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18122821 | 0.98 | KDM4E (0.63) | KDM4EKMT2AALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL14533055 | 0.95 | — | — | |
| SCHEMBL3715654 | 0.90 | — | — | |
| SCHEMBL807124 | 0.79 | KDM4E (1.00) | KDM4EKMT2ACYP1A2PKM | |
| SCHEMBL7870008 | 0.79 | KDM4E (0.59) | KDM4EKMT2A | |
| SCHEMBL18122804 | 0.79 | KDM4E (0.59) | KDM4EKMT2AALDH1A1OPRL1 | |
| SCHEMBL1226440 | 0.79 | KDM4E (0.41) | KDM4EKMT2AALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL10280093 | 0.78 | KDM4E (0.57) | KDM4EKMT2AALDH1A1CYP2D6CYP1A2 | |
| SCHEMBL3265376 | 0.78 | KMT2A (0.42) | KDM4EKMT2AALDH1A1SMN1; SMN2OPRL1 | |
| SCHEMBL13817485 | 0.78 | KDM4E (0.57) | KDM4EKMT2AOPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062975-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | SPRING MILL PHARMA, INC. | 2023-03-02 | — | — | US | disclosed |
| US-9845292-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-12-19 | — | — | US | disclosed |
| US-20160289184-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | HAUSCH, FELIX (DE) | 2016-10-06 | — | — | US | disclosed |
| EP-3071036-A1 | PESTICIDAL COMPOSITIONS AND RELATED METHODS | Dow AgroSciences LLC (US) | 2016-09-28 | — | — | EP | disclosed |
| WO-2015061165-A1 | PESTICIDAL COMPOSITIONS AND RELATED METHODS | DOW AGROSCIENCES LLC (US) | 2015-04-30 | — | — | WO | disclosed |
| WO-2010031820-A1 | GLUCOSIDE DERIVATIVES AND USES THEREOF AS SGLT INHIBITORS | NOVARTIS AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| US-20090156624-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS INC (US) | 2009-06-18 | — | — | US | disclosed |
| US-7405194-B2 | Therapeutic agents and methods of use thereof for the treatment of melanoma | PRAECIS PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20070254843-A1 | Methods for treating bone associated diseases by the use of methionine aminopeptidase-2 inhibitors | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070117758-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| US-7157420-B2 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062975-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | KDM4E 3751/4885KMT2A 4016/4885ALDH1A1 3850/4885 |
| US-20070117758-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | METAP2, METAP1, ADM2 | KDM4E 4207/4885KMT2A 4136/4885ALDH1A1 4016/4885 |
| US-20160289184-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | FKBP5, FKBP1A, FKBP1B | KDM4E 4102/4885KMT2A 4481/4885ALDH1A1 2327/4885 |
| US-20070254843-A1 | Methods for treating bone associated diseases by the use of methionine aminopeptidase-2 inhibitors | METAP2, ENPEP, METAP1 | KDM4E 1198/4885KMT2A 467/4885ALDH1A1 2702/4885 |
| US-20090156624-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, DNPEP | KDM4E 1216/4885KMT2A 446/4885ALDH1A1 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.